Daré Bioscience, Inc. (DARE) News
Follow Daré Bioscience, Inc. (DARE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Daré Bioscience, Inc. Secures U.S. Patent Extending DARE-HPV Protection to 2039
Daré Bioscience announced a new U.S. patent covering topical lopinavir/ritonavir for HPV-related cervical pathologies, expected to protect DARE-HPV into at least 2039. The Phase 2 study is underway with topline results e
NEWS | Sep 28, 2026, 12:28 PM UTC
L
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infectionDARE-HPV Phase 2 study underway with topline results expected in
REGULATION | Sep 28, 2026, 12:21 PM UTC
L
Daré Bioscience CEO joins virtual investor “Why Now” series
Daré Bioscience CEO Sabrina Martucci Johnson participates in the Virtual Investor “Why Now” on-demand series.
EQUITY | Aug 27, 2026, 01:08 PM UTC
L
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
EQUITY | Aug 27, 2026, 01:01 PM UTC
L
DARE - Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
DARE - Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
EQUITY | Aug 27, 2026, 01:01 PM UTC
L
Dare Bioscience files for resale of up to 8,934,345 common shares
Dare Bioscience has filed to permit the resale of up to 8,934,345 shares of common stock.
REGULATION | Aug 26, 2026, 09:19 PM UTC
L
DARE: Commercial launches and clinical milestones drive growth, supported by grants and new equity
DARE: Commercial launches and clinical milestones drive growth, supported by grants and new equity
EQUITY | Aug 26, 2026, 08:22 PM UTC
L
Daré Bioscience sildenafil cream data published in Menopause
Daré Bioscience reported sildenafil cream data in postmenopausal women has been published in Menopause, by The Journal of The Menopause Society.
EQUITY | Aug 26, 2026, 12:47 PM UTC
L
Daré Bioscience publishes sildenafil cream data in Menopause journal
Daré Bioscience says its sildenafil cream data in postmenopausal women have been published in the journal Menopause, The Journal of The Menopause Society.
EQUITY | Aug 26, 2026, 12:45 PM UTC
L
Daré Bioscience CEO discusses commercial transformation and pipeline momentum
Daré Bioscience CEO outlines commercial transformation and pipeline momentum, and discusses potential key catalysts during a Virtual Investor CEO Connect segment.
EQUITY | Aug 25, 2026, 12:55 PM UTC
L
DARE - DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List
DARE - DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List
EQUITY | Aug 18, 2026, 01:02 PM UTC
M
Daré Bioscience prices $6.0M registered direct offering
Daré Bioscience (DARE) announces the pricing of a $6.0 million registered direct offering priced at-the-market under Nasdaq rules.
EQUITY | Aug 14, 2026, 04:45 PM UTC
L
Daré Bioscience reports Q2 2026 results and commercial inflection
Daré Bioscience reports its second quarter 2026 results and highlights a commercial inflection as its multi-product women’s health strategy advances, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:01 PM UTC
L
DARE - Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026 - Cli
DARE - Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026
EARNINGS | Aug 06, 2026, 01:05 PM UTC
L
DARE Launches Flora Sync
Dare Bioscience CEO discusses upcoming launch of Flora Sync LF5 in virtual investor segment, highlighting revenue opportunity
EARNINGS | Jun 25, 2026, 01:05 PM UTC